Biaxin Heart Risks Result in FDA Warning for Individuals with Heart Disease

Federal regulators warn that the side effects of Biaxin, a widely used antibiotic, could increase the risk of serious heart problems or death for patients with heart disease. 

The FDA issued a drug safety communication on Thursday, indicating that doctors should prescribe Biaxin (clarithromycin) with caution among individuals with heart disease.

The warning comes following a review of data from a large clinical trial, which found that the risk of death among Biaxin patients with heart disease was significantly higher compared with patients given a placebo.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

The FDA announced that it is adding a new warning about the increased risk of death in patients with heart disease, and recommends doctors use another antibiotic when treating such patients. The agency is also adding the study’s results to Biaxin warning labels.

“There is no clear explanation for how clarithromycin would lead to more deaths than placebo,” the FDA warning notes. “Some observational studies also found an increase in deaths or other serious heart-related problems, while others did not.”

In January 2016, study published by researchers from Hong Kong also found that the risk of heart attacks was more than double among Biaxan users, compared to those given amoxicillin. A similar study published in 2013 also found an increased risk of Biaxin heart problems among patients with chronic obstructive pulmonary disease (COPD).

Biaxin and other clarithromycin antibiotics are used to treat a wide range of infections, including those affecting the lungs, skin, ears and sinuses.The drug belongs to a class of antibiotics known as macrolides. Zithromax (azithromycin) is another antibiotic in the same class, which has also recently been linked to a risk of heart problems.

In March 2013, the FDA issued a warning about the potential side effects of Zithromax, indicating that the antibiotic may disrupt the electrical activity of the heart. Zithromax is also known as the Z-Pak or Zmax.

A May 2012 study published in the New England Journal of Medicine first warned about the potential heart risks with Zithromax. Researchers found patients were 2.5 times more likely to die due to heart related problems on a five day Zithromax treatment when they compared it to treatment with other antibiotics or no antibiotic therapy.

For Biaxin, the FDA recommends that healthcare professionals be aware of the significant risks to patients with heart disease and weigh the risks and benefits before prescribing Biaxin to any patient. The agency also advises medical professionals with heart disease of the signs and symptoms of heart problems when prescribing Biaxin.

Patients are advised to tell their doctors if they have heart disease, especially when being prescribed an antibiotic. They are also advised not to stop taking heart disease medication or an antibiotic before first talking to their healthcare professional.

The FDA also requests that healthcare professionals and patients report any adverse events or side effects related to the use of Biaxin to the FDA’s MedWatch adverse event reporting program.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Generic Depo-Provera Manufacturers Call for Birth Control Shot MDL to Be Created in NY, Not California
Generic Depo-Provera Manufacturers Call for Birth Control Shot MDL to Be Created in NY, Not California (Posted yesterday)

A growing number of lawsuits against generic Depo-Provera manufacturers have been filed throughout the federal court system, each alleging that women were not adequately warned about the risk of meningioma brain tumors from the birth control shot.

Oxbryta Class Action Lawsuit Filed by Former Users of Sickle Cell Disease Drug Recalled in 2024
Oxbryta Class Action Lawsuit Filed by Former Users of Sickle Cell Disease Drug Recalled in 2024 (Posted 2 days ago)

Former users of the recalled sickle cell disease drug Oxbryta have filed a class action lawsuit, claiming the manufacturer failed to warn consumers about risks associated with the medication, which can result in stroke and death.

Group of 20 Uber Driver Sexual Assault Lawsuits Will Be Prepared for Bellwether Trials in Dec. 2025
Group of 20 Uber Driver Sexual Assault Lawsuits Will Be Prepared for Bellwether Trials in Dec. 2025 (Posted 2 days ago)

Plaintiffs and defendants have each been directed to select 10 Uber driver sexual assault lawsuits to serve as potential bellwether trials by February 14, 2025, which will then go through case-specific discovery to prepare for early test trials.